Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection

Detalhes bibliográficos
Autor(a) principal: Cruz Filho, Álvaro Augusto Souza da
Data de Publicação: 2007
Outros Autores: Sarinho, Emanuel Sávio Cavalcanti, Ayrez, G., Martinz, C., Fox, H., Cooper, P. J.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFBA
Texto Completo: http://www.repositorio.ufba.br/ri/handle/ri/4814
Resumo: p.197–207
id UFBA-2_a2a0b7ae35c27ba0243b2ea21ae99adf
oai_identifier_str oai:repositorio.ufba.br:ri/4814
network_acronym_str UFBA-2
network_name_str Repositório Institucional da UFBA
repository_id_str 1932
spelling Cruz Filho, Álvaro Augusto Souza daSarinho, Emanuel Sávio CavalcantiAyrez, G.Martinz, C.Fox, H.Cooper, P. J.Cruz Filho, Álvaro Augusto Souza daSarinho, Emanuel Sávio CavalcantiAyrez, G.Martinz, C.Fox, H.Cooper, P. J.2011-12-12T13:58:54Z2011-12-12T13:58:54Z20071365-2222http://www.repositorio.ufba.br/ri/handle/ri/4814v. 37p.197–207Background: Although the role of immunoglobulin E (IgE) in immunity against helminth parasites is unclear, there is concern that therapeutic antibodies that neutralize IgE (anti-IgE) may be unsafe in subjects at risk of helminth infection. Objective: We conducted an exploratory study to investigate the safety of omalizumab (anti- IgE) in subjects with allergic asthma and/or perennial allergic rhinitis at high risk of intestinal helminth infection. The primary safety outcome was risk of infections with intestinal helminths during anti-IgE therapy. Methods: A randomized, double-blind, placebo-controlled trial was conducted in 137 subjects (12–30 years) at high risk of geohelminth infection. All subjects received pre-study anthelmintic treatment, followed by 52 weeks’ treatment with omalizumab or placebo. Results: Of the omalizumab subjects 50% (34/68) experienced at least one intestinal geohelminth infection compared with 41% (28/69) of placebo subjects [odds ratio (OR) 1.47, 95% confidence interval (CI) 0.74–2.95, one-sided P=0.14; OR (adjusted for study visit, baseline infection status, gender and age) 2.2 (0.94–5.15); one-sided P = 0.035], providing some evidence for a potential increased incidence of geohelminth infection in subjects receiving omalizumab. Omalizumab therapy was well tolerated, and did not appear to be associated with increased morbidity attributable to intestinal helminths as assessed by clinical and laboratory adverse events, maximal helminth infection intensities and additional anthelmintic requirements. Time to first infection (OR 1.30, 95% CI 0.79–2.15, one-sided P = 0.15) was similar between treatment groups. Infection severity and response to anthelmintics appeared to be unaffected by omalizumab therapy. Conclusions: In this exploratory study of allergic subjects at high risk of helminth infections, omalizumab therapy appeared to be safe and well tolerated, but may be associated with a modest increase in the incidence of geohelminth infection.Submitted by Ana Valéria de Jesus Moura (anavaleria_131@hotmail.com) on 2011-12-12T13:58:54Z No. of bitstreams: 1 cea0037-0197.pdf: 313668 bytes, checksum: 61ad8f3f2a379cac4ed138ad13bb884a (MD5)Made available in DSpace on 2011-12-12T13:58:54Z (GMT). No. of bitstreams: 1 cea0037-0197.pdf: 313668 bytes, checksum: 61ad8f3f2a379cac4ed138ad13bb884a (MD5) Previous issue date: 2007Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infectionClinical & Experimental Allergyinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleengreponame:Repositório Institucional da UFBAinstname:Universidade Federal da Bahia (UFBA)instacron:UFBAinfo:eu-repo/semantics/openAccessORIGINALcea0037-0197.pdfcea0037-0197.pdfapplication/pdf313668https://repositorio.ufba.br/bitstream/ri/4814/1/cea0037-0197.pdf61ad8f3f2a379cac4ed138ad13bb884aMD51LICENSElicense.txtlicense.txttext/plain1748https://repositorio.ufba.br/bitstream/ri/4814/2/license.txt8a4605be74aa9ea9d79846c1fba20a33MD52TEXTcea0037-0197.pdf.txtcea0037-0197.pdf.txtExtracted texttext/plain45890https://repositorio.ufba.br/bitstream/ri/4814/3/cea0037-0197.pdf.txt97045984b8694508a1e8321d81eeb22dMD53ri/48142022-07-05 14:03:17.234oai:repositorio.ufba.br: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Repositório InstitucionalPUBhttp://192.188.11.11:8080/oai/requestopendoar:19322022-07-05T17:03:17Repositório Institucional da UFBA - Universidade Federal da Bahia (UFBA)false
dc.title.pt_BR.fl_str_mv Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection
dc.title.alternative.pt_BR.fl_str_mv Clinical & Experimental Allergy
title Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection
spellingShingle Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection
Cruz Filho, Álvaro Augusto Souza da
title_short Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection
title_full Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection
title_fullStr Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection
title_full_unstemmed Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection
title_sort Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection
author Cruz Filho, Álvaro Augusto Souza da
author_facet Cruz Filho, Álvaro Augusto Souza da
Sarinho, Emanuel Sávio Cavalcanti
Ayrez, G.
Martinz, C.
Fox, H.
Cooper, P. J.
author_role author
author2 Sarinho, Emanuel Sávio Cavalcanti
Ayrez, G.
Martinz, C.
Fox, H.
Cooper, P. J.
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Cruz Filho, Álvaro Augusto Souza da
Sarinho, Emanuel Sávio Cavalcanti
Ayrez, G.
Martinz, C.
Fox, H.
Cooper, P. J.
Cruz Filho, Álvaro Augusto Souza da
Sarinho, Emanuel Sávio Cavalcanti
Ayrez, G.
Martinz, C.
Fox, H.
Cooper, P. J.
description p.197–207
publishDate 2007
dc.date.issued.fl_str_mv 2007
dc.date.accessioned.fl_str_mv 2011-12-12T13:58:54Z
dc.date.available.fl_str_mv 2011-12-12T13:58:54Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://www.repositorio.ufba.br/ri/handle/ri/4814
dc.identifier.issn.none.fl_str_mv 1365-2222
dc.identifier.number.pt_BR.fl_str_mv v. 37
identifier_str_mv 1365-2222
v. 37
url http://www.repositorio.ufba.br/ri/handle/ri/4814
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFBA
instname:Universidade Federal da Bahia (UFBA)
instacron:UFBA
instname_str Universidade Federal da Bahia (UFBA)
instacron_str UFBA
institution UFBA
reponame_str Repositório Institucional da UFBA
collection Repositório Institucional da UFBA
bitstream.url.fl_str_mv https://repositorio.ufba.br/bitstream/ri/4814/1/cea0037-0197.pdf
https://repositorio.ufba.br/bitstream/ri/4814/2/license.txt
https://repositorio.ufba.br/bitstream/ri/4814/3/cea0037-0197.pdf.txt
bitstream.checksum.fl_str_mv 61ad8f3f2a379cac4ed138ad13bb884a
8a4605be74aa9ea9d79846c1fba20a33
97045984b8694508a1e8321d81eeb22d
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFBA - Universidade Federal da Bahia (UFBA)
repository.mail.fl_str_mv
_version_ 1808459389781147648

Registros relacionados